PPL vs. GSK
PPL (PPL Corporation) and GSK (GlaxoSmithKline plc) are both stocks. PPL operates in Utilities - Regulated Electric (Utilities), while GSK operates in Drug Manufacturers - General (Healthcare). Over the past 10 years, PPL returned 3.60%/yr vs 5.35%/yr for GSK. At a 0.23 correlation, their price movements are largely independent.
Performance
PPL vs. GSK - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, PPL achieves a 3.97% return, which is significantly lower than GSK's 9.89% return. Over the past 10 years, PPL has underperformed GSK with an annualized return of 3.60%, while GSK has yielded a comparatively higher 5.35% annualized return.
PPL
- 1D
- 1.10%
- 1M
- 3.61%
- YTD
- 3.97%
- 6M
- 7.12%
- 1Y
- 9.14%
- 3Y*
- 13.81%
- 5Y*
- 7.88%
- 10Y*
- 3.60%
GSK
- 1D
- 0.34%
- 1M
- 6.78%
- YTD
- 9.89%
- 6M
- 10.40%
- 1Y
- 34.50%
- 3Y*
- 19.84%
- 5Y*
- 5.34%
- 10Y*
- 5.35%
PPL vs. GSK - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
PPL PPL Corporation | 3.97% | 11.38% | 23.98% | -3.77% | 0.35% | 12.88% | -16.87% | 33.41% | -3.01% | -5.19% |
GSK GlaxoSmithKline plc | 9.89% | 51.23% | -5.14% | 9.71% | -33.41% | 26.74% | -17.72% | 29.24% | 13.79% | -2.97% |
Correlation
The correlation between PPL and GSK is 0.15, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.15 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.25 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.28 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.27 |
Correlation (All Time) Calculated using the full available price history since Jul 9, 1986 | 0.23 |
The correlation between PPL and GSK shifts across timeframes, from 0.15 (1 year) to 0.28 (5 years), reflecting how their relationship changes across market environments.
Fundamentals
PPL:
$27.14B
GSK:
$108.04B
PPL:
$1.63
GSK:
£2.85
PPL:
21.98
GSK:
13.90
PPL:
18.41
GSK:
0.93
PPL:
2.88
GSK:
2.47
PPL:
1.24
GSK:
3.42
PPL:
$9.31B
GSK:
£32.78B
PPL:
$4.34B
GSK:
£23.87B
PPL:
$3.38B
GSK:
£11.30B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
PPL vs. GSK — Risk / Return Rank
PPL
GSK
PPL vs. GSK - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for PPL Corporation (PPL) and GlaxoSmithKline plc (GSK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| PPL | GSK | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.64 | ||
| Sortino ratioReturn per unit of downside risk | -0.94 | ||
| Omega ratioGain probability vs. loss probability | 1.08 | 1.20 | -0.12 |
| Calmar ratioReturn relative to maximum drawdown | 0.57 | 1.58 | -1.01 |
| Martin ratioReturn relative to average drawdown | 1.49 | 3.92 | -2.43 |
Loading charts...
Drawdowns
PPL vs. GSK - Drawdown Comparison
The maximum PPL drawdown since its inception was -55.38%, roughly equal to the maximum GSK drawdown of -55.70%. Use the drawdown chart below to compare losses from any high point for PPL and GSK.
Loading charts...
Drawdown Indicators
| PPL | GSK | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -55.38% | -55.70% | +0.32% |
Max Drawdown (1Y)Largest decline over 1 year | -13.29% | -18.63% | +5.34% |
Max Drawdown (3Y)Largest decline over 3 years | -18.84% | -28.46% | +9.62% |
Max Drawdown (5Y)Largest decline over 5 years | -24.73% | -50.10% | +25.37% |
Max Drawdown (10Y)Largest decline over 10 years | -48.73% | -50.10% | +1.37% |
Current DrawdownCurrent decline from peak | -9.22% | -11.92% | +2.70% |
Average DrawdownAverage peak-to-trough decline | -15.62% | -18.87% | +3.25% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.12% | 8.28% | -3.16% |
Volatility
PPL vs. GSK - Volatility Comparison
The current volatility for PPL Corporation (PPL) is 5.51%, while GlaxoSmithKline plc (GSK) has a volatility of 6.81%. This indicates that PPL experiences smaller price fluctuations and is considered to be less risky than GSK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| PPL | GSK | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 5.51% | 6.81% | -1.30% |
Volatility (6M)Calculated over the trailing 6-month period | 12.76% | 18.49% | -5.73% |
Volatility (1Y)Calculated over the trailing 1-year period | 16.94% | 27.06% | -10.12% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 18.73% | 25.08% | -6.35% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 22.78% | 22.89% | -0.11% |
Dividends
PPL vs. GSK - Dividend Comparison
PPL's dividend yield for the trailing twelve months is around 3.11%, less than GSK's 3.26% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
GSK GlaxoSmithKline plc | 3.26% | 3.42% | 4.60% | 3.75% | 5.47% | 4.99% | 5.59% | 4.35% | 5.65% | 5.83% | 6.86% | 5.93% |
PPL PPL Corporation | 3.11% | 3.11% | 3.17% | 3.54% | 2.99% | 5.52% | 5.89% | 4.60% | 5.79% | 5.11% | 4.46% | 11.74% |
Financials
PPL vs. GSK - Financials Comparison
This section allows you to compare key financial metrics between PPL Corporation and GlaxoSmithKline plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
PPL vs. GSK - Profitability Comparison
PPL - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, PPL Corporation reported a gross profit of 1.92B and revenue of 2.77B. Therefore, the gross margin over that period was 69.3%.
GSK - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported a gross profit of 5.75B and revenue of 7.63B. Therefore, the gross margin over that period was 75.4%.
PPL - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, PPL Corporation reported an operating income of 745.00M and revenue of 2.77B, resulting in an operating margin of 26.9%.
GSK - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported an operating income of 2.29B and revenue of 7.63B, resulting in an operating margin of 30.1%.
PPL - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, PPL Corporation reported a net income of 452.00M and revenue of 2.77B, resulting in a net margin of 16.3%.
GSK - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported a net income of 1.74B and revenue of 7.63B, resulting in a net margin of 22.8%.
Frequently Asked Questions
PPL and GSK have a correlation of 0.15, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
GSK has higher volatility (6.81%) compared to PPL (5.51%). In terms of maximum drawdown, PPL dropped -55.38% vs GSK's -55.70%.
GSK currently has the higher Sharpe Ratio (1.09 vs 0.45), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for PPL and GSK
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer